DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for hepatosplenic T-cell lymphoma — screening already-approved drugs against its 35-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHepatosplenic T-cell lymphoma maps to a 35-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hepatosplenic t-cell lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
Hepatosplenic T-cell lymphoma is a rare T-cell malignancy with an aggressive clinical course and poor prognosis. Up to 20% of cases arise in the setting of chronic immune suppression or immune dysregulation. The disease typically involves spleen, liver, and bone marrow without lymphadenopathy, and conventional chemotherapy regimens produce poor outcomes. The NCCN Guidelines Insights from 2020 note that diagnosis and management are challenging because of the disease’s rarity and the absence of lymphadenopathy.
A 2021 review of treatment challenges states that specific first-line treatment recommendations remain debatable. Published case reports and series agree that allogeneic stem cell transplant should be offered as consolidation after response to chemotherapy for all eligible patients. The review cites two recent clinical examples to support the view that specific chemotherapy followed by first-line allogeneic transplantation, when a donor is available, represents a treatment of choice. The same review summarises recent molecular studies that suggest potential targets for new therapeutic strategies, and claims major progress in improving outcome using intensive chemotherapy and allogeneic transplantation, but provides no response rates, survival figures, or sample sizes.
A 2017 commentary on the genetics of hepatosplenic T-cell lymphoma reports frequent mutations of STAT5B, PIK3CD, and the histone methyltransferase SETD2. The authors suggest these findings may help guide translational efforts to target the disease. No clinical outcomes are reported in that commentary.
What is still missing are prospective clinical trials large enough to establish a standard first-line regimen, given the extreme rarity of the disease. No randomised data exist to compare chemotherapy alone versus chemotherapy plus allogeneic transplant. The molecular targets identified have not yet been tested in patients with hepatosplenic T-cell lymphoma. Funding for multi-centre collaborative trials and reliable patient stratification by genetics or immune status remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the National Comprehensive Cancer Network · 2020 · 62 citations · open access
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
AbstractHepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.
AbstractPURPOSE OF REVIEW: Hepatosplenic lymphoma (HSTCL) is a rare T-cell malignancy occurring in young males, associated with immune deficiency in 20% of the cases which, despite aggressive treatments, has a poor survival. Specific recommendations for first-line treatment remain debatable. RECENT FINDINGS: Published data covering case reports or series of HSTCL concur that allogeneic stem cell transplant should be proposed as a consolidation after response to chemotherapy in all patients eligible for transplant. In the light of two recent clinical examples, we also confirm that specific chemotherapy and a first-line consolidation with allogeneic transplantation when a donor is available to represent a treatment of choice these rare and distinctive lymphomas. Recent molecular studies are summarized in this review and suggest potential targets for new therapeutic strategies. SUMMARY: Major progresses have been achieved in improving the outcome of HSTCL l patients using intensive chemotherapy and allogeneic transplantation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
